[K23] Dissecting the Heterogeneous Molecular Mechanisms Underlying Multiple Sclerosis Progression
Ente: National Institute of Neurological Disorders and Stroke
Scadenza: 2030-07-31
Importo max: 198.928 EUR
Paese: US
Descrizione
Abstract
Multiple sclerosis is the most common cause of non-traumatic disability in young adults, with an estimated total
economic burden of $85.4 billion. Irreversible disability accumulation is the most challenging, unmet need
in care for people with multiple sclerosis (pwMS) and drives socioeconomic burden. Disability
accumulates in two different clinical contexts: Progression independent of relapse activity (PIRA, ~ 80%) and
relapse-associated worsening (RAW, ~20%). Both are driven by a complex interplay of immune- and non-
immune processes. Body fluid biomarkers offer a unique opportunity to disentangle the complicated
pathophysiology of progression, which cannot be studied with sufficient fidelity in vitro or using animal models. I
spearheaded a collaboration between US and European cohorts with > 12,000 visits to assess neuroaxonal
injury in pwMS. This work revealed that central nervous system (CNS) injury occurred months to years preceding
progression (pre-PIRA/ pre-RAW). Building upon this research, the primary objective of this grant is to elucidate
the cellular constituents and related mechanisms of CNS injury during pre-progression.
To that end, I plan to acquire the skills and tools to perform a proteome-wide analysis of serum samples from
two international cohorts from the US and Germany. The Olink® Explore HT kit can measure up to 5400 proteins
using antibody-based proximity extension technology. Among those proteins are many CNS-driven markers that
cannot be measured otherwise. This proteomic analysis will help us determine the magnitude of astrocyte
response during pre-PIRA, define the severity and dynamics of oligodendrocyte and myelin injury in pre-PIRA
and how it relates to neuroaxonal injury and characterize the role of synaptic injury during that critical window of
CNS injury (Aim 1). The dataset generated during Aim 1 will be further analyzed in Aims 2 and 3 to define the
driving mechanisms of PIRA at different disease stages, how PIRA differs from RAW, and what distinct markers
can characterize each process.
This project is anticipated to unravel a set of proteins/ protein pathways of particular significance for MS
progression. In my future independently funded lab, I aim to build on this work by establishing the next-stage
progression-focused assays and defining their clinical context of use in MS.
Istituzione: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
PI: Ahmed Abdelhak
Progetto: 5K23NS140543-02
Settori: National Institute of Neurological Disorders and Stroke
Vai al bando originale
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.